ArticleJournal of advanced research2026
MolProphecy: Bridging medicinal chemists' knowledge and molecular pre-trained models via a multi-modal framework.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn drug discovery, the tacit domain knowledge of experts plays a critical role in guiding molecular design and decision-making.However, existing molecular pre-trained models rarely incorporate such expert knowledge, leading to suboptimal molecular design decisions.
objectivesThis study proposes MolProphecy, a proxy-human-in-the-loop (proxy-HITL) multi-modal framework that integrates chemists' domain knowledge with structural molecular information to improve predictive accuracy and interpretability in drug discovery.
methodsMolProphecy simulates chemist reasoning using ChatGPT to generate expert-level chemist insights for target molecules.This knowledge is encoded by a large language model (LLM) and fused with graph-based molecular features via a gated multi-head cross-attention module.The framework jointly reasons over human-derived and structural information.
resultsMolProphecy consistently outperforms baseline models across nine MoleculeNet benchmarks.For illustration, on FreeSolv it achieves an RMSE of 0.796, a 9.1% reduction over the best baseline.On BACE, SIDER, and ClinTox, MolProphecy improves AUROC by 5.39%, 1.43%, and 1.06%, respectively.In addition, MolProphecy demonstrates strong generalization on an independent solubility dataset, demonstrating robustness and applicability of our multi-modal fusion framework.
conclusionMolProphecy provides a generalizable framework for molecular property prediction by integrating simulated chemist expertise with structural data. Its design allows simulated input to be replaced with real chemist knowledge without retraining, establishing a pathway toward collaborative and interpretable drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.